Hemispherx Highlights Year-To-Date Progress, Outlines Key Objectives
19. Dezember 2017 08:30 ET
|
Hemispherx Biopharma, Inc.
Letter to Shareholders Posted on Website Revenue Up, Burn Rate Down Dramatically; Progress Cited with FDA Discussions on Ampligen; Manufacturing Facility for FDA-Approved Alferon N Fully Repaired;...
Hemispherx Biopharma Announces Conference Call to Provide Quarterly Business Update on November 15, 2016
10. November 2016 08:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced today that it anticipates filing its 2016 third quarter financial...
Hemispherx Biopharma's Judgment Unanimously Affirmed Against Cato Capital
26. August 2015 10:00 ET
|
AIM ImmunoTech Inc.
WILMINGTON, Del., Aug. 26, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced that on Friday the Third Circuit Court of Appeals upheld the...